The study, which was conducted by an independent researcher, has not yet been published, but innoVactiv says it will pursue its publication “by the end of the summer”.
According to the firm’s CEO Patrice Dionne, the findings add extra backing to the ingredient’s ability to help manage blood glucose levels and to reduce the risk of developing insulin resistance. “We’ve shown that InSea2 can help reduce the insulin peak after a high-carb meal, which could help prevent the risk of developing type 2 diabetes,” he told NuraIngredients-USA.com this morning.
InSea2 was launched in 2008 and is already being used in dietary supplement products in Canada, the US and Taiwan. It is a polyphenol blend extracted from two forms of brown seaweed.
Reduced blood glucose
The findings of the new trial, completed last month, show that at a dose of 7.5mg/kg of body weight, InSea2 “significantly reduced” the impact of sucrose on blood glucose levels in both lean and obese Zucker rats.
The ingredient was administered to the rats at the same time as a sucrose load. In lean rats, blood glucose levels were reduced by 38 percent and 51 percent after 30 and 60 minutes respectively. In obese rats, blood glucose levels were reduced by 25 percent.
Other findings revealed that the ingredient works as a sucrase inhibitor, with limited or no inhibitory action on maltase or lactase, said Dionne.
“These recent findings represent a true innovation compared to other mono-action starch blockers on the market that only block α-amylase or α glucosidase,” he said.
“By using our clinically demonstrated InSea2, formulators can address starch and sugar absorption with a single active ingredient, providing cost and formulation benefits in the design of new dietary supplements”
So far, the largest market for the ingredient has been the US. innoVactiv launched it in the European market at the Vitafoods trade show last week.